Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The U.S. Food and Drug Administration is advising diabetes patients who use Lantus, a form of synthetic insulin designed to last longer in the body, to keep using the drug despite a possible link to cancer uncovered by 3 European studies. Manufactured by Sanofi-Aventis of Paris, France, Lantus is a top-selling diabetes drug with sales reaching 2.45 Euros in 2008, about 3.5 billion dollars.

Read the rest of this entry »